ConductScience.org, home

Paper8286205

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

Seymour MT and 7 others. Br J Cancer, 1994. Cited by 61 papers, by iCite.

Cite this record

ConductScience Library. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Papers, record 8286205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8286205

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
PubMed
Journal
Br J Cancer
PubMed
Year
1994
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study
PubMed
Citations, by iCite
61
iCite
Relative citation ratio, by iCite
2.21
iCite
Revised in PubMed
2019-05-15
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Seymour MTM T
2Mansi JLJ L
3Gallagher CJC J
4Gore MEM E
5Harper PGP G
6Evans TRT R
7Edmonds PMP M
8Slevin MLM L

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarboplatinMajor topic
CisplatinMajor topic
EtoposideMajor topic
Ovarian NeoplasmsMajor topic
Administration, Oral
Adult
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance
Epithelium
Female
Humans
Middle Aged
Prospective Studies

Source PubMed

Download CSV of topics

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17340985A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7340985PubMed
24054715Phase II trial of VP-16-213 in advanced ovarian carcinoma.Gynecol Oncol1985https://conductscience.org/library/papers/4054715PubMed
33000790Variable bioavailability following repeated oral doses of etoposide.Eur J Cancer Clin Oncol1985https://conductscience.org/library/papers/3000790PubMed
43082726Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.Gynecol Oncol1986https://conductscience.org/library/papers/3082726PubMed
53102056
Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Cancer Treat Rep1987https://conductscience.org/library/papers/3102056PubMed
62736711A phase II study of mitozantrone in advanced carcinoma of the ovary.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2736711PubMed
72569287Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.Ann Intern Med1989https://conductscience.org/library/papers/2569287PubMed
82549204A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.J Clin Oncol1989https://conductscience.org/library/papers/2549204PubMed
92509641Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.J Clin Oncol1989https://conductscience.org/library/papers/2509641PubMed
102104819Hexamethylmelamine as a single second-line agent in ovarian cancer.Gynecol Oncol1990https://conductscience.org/library/papers/2104819PubMed
112154858Phase II study of daily oral etoposide in refractory germ cell tumors.Semin Oncol1990https://conductscience.org/library/papers/2154858PubMed
122154861Chronic daily administration of oral etoposide.Semin Oncol1990https://conductscience.org/library/papers/2154861PubMed
132318446Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.Gynecol Oncol1990https://conductscience.org/library/papers/2318446PubMed
142195412Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.Oncology1990https://conductscience.org/library/papers/2195412PubMed
151694980Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.Oncology1990https://conductscience.org/library/papers/1694980PubMed
162170588Low-dose oral etoposide: a new role for an old drug?J Clin Oncol1990https://conductscience.org/library/papers/2170588PubMed
172145914Epirubicin for pretreated advanced ovarian cancer.Eur J Cancer1990https://conductscience.org/library/papers/2145914PubMed
181357110Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.J Clin Oncol1992https://conductscience.org/library/papers/1357110PubMed
198382514Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.Br J Cancer1993https://conductscience.org/library/papers/8382514PubMed
208353095Low-dose oral etoposide in epithelial cancer of the ovary.Ann Oncol1993https://conductscience.org/library/papers/8353095PubMed

Download CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.

PMIDTitleJournalYearIn PapersSource
27099605Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy.Case Rep Oncol2016https://conductscience.org/library/papers/27099605PubMed
22045509Recurrent ovarian cancer: when and how to treat.Curr Oncol Rep2011https://conductscience.org/library/papers/22045509PubMed
20480200Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer.Int J Clin Oncol2010https://conductscience.org/library/papers/20480200PubMed
15956976Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.Br J Cancer2005https://conductscience.org/library/papers/15956976PubMed
15756278Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.Br J Cancer2005https://conductscience.org/library/papers/15756278PubMed
12875610Pharmacological factors influencing anticancer drug selection in the elderly.Drugs Aging2003https://conductscience.org/library/papers/12875610PubMed
11857002Weekly platinum chemotherapy for recurrent ovarian cancer.Br J Cancer2002https://conductscience.org/library/papers/11857002PubMed
11122800Salvage therapy for ovarian cancer.Curr Oncol Rep1999https://conductscience.org/library/papers/11122800PubMed
10933513Drug therapy for gynaecological cancer in older women.Drugs Aging2000https://conductscience.org/library/papers/10933513PubMed
10711841Oral etoposide for the treatment of recurrent ovarian cancer.Drugs1999https://conductscience.org/library/papers/10711841PubMed
7497587Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497587PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MUC1694025PubTator's text mininghttps://conductscience.org/library/genes/94025

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8286205

GET https://conductscience.org/api/papers/v1/8286205/authors